PPARG and cancer: Second, the molecular markers reported to be useful in FNA cytology to help guide management, such as RAS and TERT promoter mutations and RET/PTC and PAX8/PPARγ rearrangements, were not detected in this study, which may have caused some of the malignant tumors to be missed.